Anetumab (Anti-Mesothelin)

製品コードA2673 別名: Anti-MSLN Antibody 純度：99%

Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 58200	国内在庫あり
1mg*5	JPY 144600	お問い合わせ
1mg*25	JPY 432600	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る： A267301 純度： 99% タンパク質濃度： 7.73mg/ml 内毒素：＜1EU/mg

生物活性

製品説明	Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD.

参考
https://pubmed.ncbi.nlm.nih.gov/24714131/

参考

https://pubmed.ncbi.nlm.nih.gov/24714131/

製品説明

CAS No.	1954758-84-9
Molecular Weight	143.8
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06885697	RECRUITING	Drug: cyclophosphamide\|Drug: fludarabine	Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms	National Cancer Institute (NCI)	2025-07-08	PHASE1
NCT03816358	ACTIVE_NOT_RECRUITING	Drug: Gemcitabine Hydrochloride	Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8	National Cancer Institute (NCI)	2019-12-09	PHASE1
NCT03587311	ACTIVE_NOT_RECRUITING	Drug: Paclitaxel	Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma	National Cancer Institute (NCI)	2018-10-12	PHASE2
NCT07010523	RECRUITING	Drug: Fludarabine\|Drug: Cyclophosphamide	Mesothelin-positive Advanced Malignant Solid Tumors	First Affiliated Hospital of Zhejiang University	2024-10-15
NCT05848999	UNKNOWN		Mesothelin-positive Advanced Malignant Solid Tumors	Zhejiang University	2023-04-27	PHASE1
NCT05531708	WITHDRAWN	Drug: Fludarabine\|Drug: Cyclophosphamide	Mesothelin-positive Advanced Refractory Solid Tumors	Shanghai Pudong Hospital	2021-04-02	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-26)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須